Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
Información
- DOI:
- https://doi.org/10.1002/14651858.CD009510Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 07 diciembre 2011see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Salud ocular y de la visión
- Copyright:
-
- Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Conceiving the review: Cochrane Eyes and Vision Group
Designing the review: DM, DC
Co‐ordinating the review: DM
Data collection for the review:
‐ Designing electronic search strategies: Cochrane Eyes and Vision Group editorial base
‐ Undertaking manual searches: DM
‐ Screening search results: DM, DC
‐ Organising retrieval of papers: DM, DC
‐ Screening retrieved papers against inclusion criteria: DM, DC
‐ Appraising quality of papers: DM, DC
‐ Extracting data from papers: DM, DC
‐ Writing to authors of papers for additional information: DM
‐ Providing additional data about papers: DM, DC
‐ Obtaining and screening data on unpublished studies: DM, DC
Data management for the review:
‐ Entering data into RevMan: DM
‐ Checking that data entered into RevMan is correct: DM, DC
Analysis of data: CB, DM, DC
Interpretation of data:
‐ Providing a methodological perspective: CB, DM, DC
‐ Providing a clinical perspective: DM, DC
‐ Providing a policy perspective: CB, DC
Writing the review: DM
Providing general advice on the review: CB, DM, DC
Sources of support
Internal sources
-
NIHR, UK.
Catey Bunce acknowledges financial support from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.
External sources
-
No sources of support supplied
Declarations of interest
No authors have any financial or proprietary interest in any product mentioned.
Acknowledgements
The Cochrane Eyes and Vision Group (CEVG) will create and execute the electronic searches. We would like to acknowledge and thank Anupa Shah for her help and assistance in this protocol. We thank Tasanee Braithwaite and Gianni Virgili for their comments on this protocol.
Richard Wormald (Co‐ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2020 Jul 07 | Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion | Review | Zaid Shalchi, Omar Mahroo, Catey Bunce, Danny Mitry | |
| 2013 Jan 31 | Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion | Review | Danny Mitry, Catey Bunce, David Charteris | |
| 2011 Dec 07 | Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion | Protocol | Danny Mitry, Catey Bunce, David Charteris | |
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
- Angiogenesis Inhibitors [*administration & dosage, adverse effects];
- Antibodies, Monoclonal, Humanized [*administration & dosage, adverse effects];
- Bevacizumab [administration & dosage];
- Intravitreal Injections;
- Laser Coagulation;
- Laser Therapy;
- Macular Edema [*drug therapy, etiology, surgery];
- Randomized Controlled Trials as Topic;
- Ranibizumab [administration & dosage];
- Receptors, Vascular Endothelial Growth Factor [administration & dosage];
- Recombinant Fusion Proteins [administration & dosage];
- Retinal Vein Occlusion [*complications];
- Salvage Therapy [methods];
- Steroids [administration & dosage];
- Vascular Endothelial Growth Factor A [*antagonists & inhibitors];
- Visual Acuity [drug effects];
Medical Subject Headings Check Words
Humans;
